KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Travere Therapeutics (TVTX) Other Gross PP&E Adjustments (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Other Gross PP&E Adjustments for 11 consecutive years, with -$10.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Gross PP&E Adjustments rose 34.36% year-over-year to -$10.4 million, compared with a TTM value of -$10.4 million through Dec 2025, up 34.36%, and an annual FY2025 reading of -$10.4 million, up 34.36% over the prior year.
  • Other Gross PP&E Adjustments was -$10.4 million for Q4 2025 at Travere Therapeutics, up from -$11.5 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at -$10.4 million in Q4 2025 and bottomed at -$29.7 million in Q4 2022.
  • Average Other Gross PP&E Adjustments over 5 years is -$19.6 million, with a median of -$19.9 million recorded in 2023.
  • The sharpest move saw Other Gross PP&E Adjustments surged 37.3% in 2021, then dropped 9.79% in 2022.
  • Year by year, Other Gross PP&E Adjustments stood at -$27.0 million in 2021, then decreased by 9.79% to -$29.7 million in 2022, then increased by 16.66% to -$24.7 million in 2023, then skyrocketed by 35.81% to -$15.9 million in 2024, then soared by 34.36% to -$10.4 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for TVTX at -$10.4 million in Q4 2025, -$11.5 million in Q3 2025, and -$12.3 million in Q2 2025.